Our Past Clinical Studies

Call us!

Ashland: 541.488.3192

Grants Pass: 541.956.6471

Emergency: 911

Our Past Studies

These are some of the clinical trials that Retina & Vitreous of Southern Oregon has participated in. Please check our current studies section for recent activity.

  • This nine-month, Phase 2A clinical trial is evaluating the safety and efficacy of intravitreous iSONEP™ (Sonepcizumab) as either monotherapy or adjunctive therapy to Lucentis®, Avastin® or Eyelea®, versus Lucentis®, Avastin® or Eylea® alone, for the treatment of Wet AMD.
  • This 24-month, Phase 3 trial is establishing the safety and efficacy of intravitreous Fovista™ (anti PDGF-B pegylated aptamer) administrated in combination with Lucentis®, compared to Lucentis® monotherapy in subjects with Wet AMD.
  • This 9-month, Phase 3, placebo-controlled trial is establishing the safety and efficacy of Gevokizumab in subjects with non-infections Uveitis. This trial is for patients with active non-Infectious intermediate, posterior or pan-uveitis.
  • This 18-month, Phase 3, placebo-controlled trial is establishing the safety and efficacy of Gevokizumab in subjects with non-infections Uveitis who are currently controlled with systemic treatment.
  • This 12-month, Phase 2 trial compares the safety and efficacy of ESBA1008 versus Eylea® in subjects with Wet AMD. Enrollment for this trial is currently closed.

Login